DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place becaus...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaltenbach, Robert F., Trainor, George, Getman, Daniel, Harris, Greg, Garber, Sena, Cordova, Beverly, Bacheler, Lee, Jeffrey, Susan, Logue, Kelly, Cawood, Pamela, Klabe, Ronald, Diamond, Sharon, Davies, Marc, Saye, Joanne, Jona, Janan, Erickson-Viitanen, Susan
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2001
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC90777/
https://ncbi.nlm.nih.gov/pubmed/11600351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.11.3021-3028.2001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars